Mounjaro®
Starting from £179.99/mo
Start journey Learn moreHow Mounjaro and Wegovy differ, where they overlap, and what switching actually looks like
You're on one and wondering about the other, here's why combining them isn't the answer
Picture this: you've been on Wegovy for a few months, your weight loss has slowed, and you've read that Mounjaro produced stronger average results in a head-to-head trial. The instinct is understandable, if one is good, could two be better?
The short answer is no. Wegovy contains semaglutide, a GLP-1 receptor agonist. Mounjaro contains tirzepatide, which activates both the GLP-1 and GIP receptors. These are distinct mechanisms, but they share significant physiological overlap: both slow gastric emptying, both suppress appetite through gut-hormone pathways, and both carry a gastrointestinal side-effect profile that stacks with dose. If you've wondered whether mixing semaglutide and Mounjaro could somehow combine the benefits, the clinical reality is that running them simultaneously would almost certainly intensify nausea, vomiting and the risk of dehydration, without any evidence that the combination produces better weight outcomes than either medicine at an optimised dose alone.
There is no licensed combination regimen. No clinical trial has studied it in humans for weight management. A responsible prescriber will not issue a prescription for both concurrently. If you're curious about whether a combined regimen of Mounjaro and Wegovy has any evidence base, the honest answer is: none that would support clinical use.
What the evidence does support is switching, and that is a different conversation entirely. The clinical comparison between Wegovy and Mounjaro shows meaningfully different average outcomes at top doses, which is exactly the kind of factor a prescriber weighs when reviewing your progress.
What the trial data actually shows, side by side
The SURMOUNT-5 trial published in the New England Journal of Medicine (2025) is the only published randomised head-to-head comparison. It enrolled 751 adults with obesity but without type 2 diabetes over 72 weeks, comparing tirzepatide 15mg against semaglutide 2.4mg. Tirzepatide produced greater average weight reduction. That finding informed NICE's committee discussions when appraising tirzepatide under TA1026.
It is worth noting that Wegovy now has a 7.2mg maintenance dose (approved by the MHRA on 14 April 2026) with trial data showing around 20.7% average weight loss over 72 weeks, which narrows the gap with tirzepatide considerably. Neither medicine is categorically superior for every individual; starting point, tolerability and any underlying conditions all shape outcomes.
| Feature | Mounjaro (tirzepatide) | Wegovy (semaglutide) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 receptor agonist | GLP-1 receptor agonist |
| Average weight loss (pivotal trial) | ~20–21% at 15mg (SURMOUNT-1, NEJM) | ~15% at 2.4mg (STEP 1, NEJM); ~20.7% at 7.2mg |
| UK licence (weight management) | Adults, BMI ≥30 or ≥27 with a weight-related condition | Adults, BMI ≥30 or ≥27 with a weight-related condition |
| Dosing frequency | Once weekly injection | Once weekly injection |
| NICE recommendation | TA1026 (Dec 2024, updated Sep 2025) | TA875 (Mar 2023, specialist services, max 2 years) |
| Can be combined? | No, not licensed, not studied, not recommended | |
Both are Prescription-Only Medicines requiring clinical assessment. Side-effect profiles are broadly similar: gastrointestinal symptoms dominate in both programmes, typically peaking around dose increases and settling with time. The NHS medicines pages for tirzepatide and semaglutide cover both in accessible detail.
If Mounjaro interests you after Wegovy, switching is a recognised clinical pathway
Switching from one GLP-1 class medicine to another is different from combining them, and it is something prescribers consider regularly. The process involves stopping one treatment, allowing a wash-out or transition period determined by your prescriber, and starting the new medicine at its introductory dose. It is not a shortcut or an upgrade you self-manage.
A question our prescribers hear fairly often is whether someone can simply pick up where they left off on the dosing ladder. The answer depends on your history, how long you were on treatment, your current weight and any side-effect record. Our clinical team reviews all of this before any prescription is issued. A related question that comes up regularly is whether mixing tirzepatide and semaglutide is a viable route for people who feel they need elements of both, and the answer there is equally clear: it is not a recognised or safe approach. You can read more about the specific transition process in the guide to switching from Mounjaro to Wegovy, or in the reverse direction with restarting Mounjaro after Wegovy.
Transfer patients are asked to provide evidence of their current or most recent treatment. That is standard clinical practice, not bureaucracy, it lets the prescriber make a genuinely informed decision rather than a guess. If you'd like to understand the team behind those decisions, our clinical team profile sets out how oversight works at nume.
Which medicine suits you is a clinical decision made with our prescribers, not something a comparison table resolves. If you're ready to start that conversation, begin your free consultation and a prescriber will review your case the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.